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 Congestive heart failure (HF) can occur as a conse-
quence of hypertension, ischemic heart disease, valvular 
disease, or inherited idiopathic cardiomyopathy ( 1 ). Ac-
cording to the American Heart Association Statistical 
Committee 2008 update, 5,300,000 people suffer from this 
condition, with 660,000 new cases diagnosed each year 
( 2 ). With the advent of a wide variety of pharmacological 
and surgical treatments, the hospital discharge rate of HF 
patients has improved from 1979 to 2005, but deaths due 
to HF remain as high in 2004 as in 1994 ( 3 ). Therefore, to 
understand the underlying cause of this serious condition 
and to prevent its development, it is important to identify 
the pathophysiologic basis of the disease. 
 Cardiolipin [CL, bis-(1,2-diacyl- sn -glycero-3-phospho)-
1 ¢ -3 ¢ - sn -glycerol] is a major phospholipid of the mitochon-
drial inner membrane required for the activity of a number 
of key mitochondrial enzymes involved in cellular energy 
metabolism ( 4 ). During the development of HF, it is be-
lieved that mitochondrial energy production is unable to 
meet the requirements of the hypertrophied heart ( 5–7 ). 
Alterations in CL have been observed in human and ex-
perimental models of HF, which correlated closely with a 
loss of mitochondrial respiratory enzyme activity and 
disease progression in SHHF rats ( 8 ). However, the mech-
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 HF Patients 
 Left ventricular (LV) tissues were obtained from explanted 
hearts of patients diagnosed with idiopathic dilated cardiomyo-
pathy (IDC; 52 ± 3 years; n = 4 male, 6 female, mean ejection 
fraction 17 ± 2%). Nonfailing (NF) LV samples were obtained 
from patients who had no history of cardiac or pulmonary disease 
(46 ± 5 years; n = 4 male, 6 female; mean ejection fraction 48 ± 
2%). All hearts were dissected and fl ash frozen in a timely man-
ner to assure consistency between samples. There were no signifi -
cant differences in mean age between the IDC and NF control 
groups. Nonfailing and failing hearts were obtained via an Insti-
tutional review board approved protocol maintained by the Uni-
versity of Colorado Health Sciences Center Cardiac Tissue Bank. 
Hearts donated for research purposes were obtained under writ-
ten consent from family members of organ donors whose hearts 
could not be used for transplantation or by direct written con-
sent from end-stage heart failure patients undergoing cardiac 
transplantation. 
 Echocardiographic measurements and assessment of 
general characteristics 
 Transthoracic echocardiography was performed on SHHF rats 
at the ages of 2 months (hypertensive), 15 months (compensated 
hypertrophy), and 22 months (terminal HF) under inhaled iso-
fl urane anesthesia (5% initial, 2% maintenance) using a 12 MHz 
pediatric transducer connected to a Hewlett Packard Sonos 5500 
Ultrasound system. Short axis M-mode echocardiograms on the 
left ventricle were obtained for measurement of LV internal di-
ameters at diastole (LVIDd) and systole (LVIDs), LV fractional 
shortening (FS), ejection fraction (EF), anterior wall thickness 
(AWT) and posterior wall thickness (PWT) as described previ-
ously ( 12 ). After echocardiographic measurements, SHHF rats 
were euthanized and the heart, liver, kidney and lungs were sur-
gically removed and weighed to check the signs of hypertrophy 
and HF. 
 Preparation of subcellular fractions and assay of enzyme 
activities 
 Subcellular fractions were prepared from myocardial tissue 
as previously described ( 8, 16 ). All isolation procedures were 
performed at 4°C. A 10% LV homogenate was prepared in buf-
fer containing 0.25 M sucrose, 10 mM Tris-HCl, 0.145 M NaCl 
(pH 7.4) followed by homogenization with 50 strokes of a tight 
fi tting Dounce A homogenizer. The homogenate was centri-
fuged at 1,000  g for 10 min, and the resulting supernatant cen-
trifuged at 12,000  g for 15 min. The resulting pellet was 
resuspended in 0.5 ml of homogenizing buffer by a tight fi tting 
Dounce A homogenizer and used as the source of mitochon-
drial fraction for assay of mitochondrial enzyme activities. The 
supernatant was centrifuged at 100,000  g for 1 h. The resulting 
pellet was resuspended in 0.5 ml of homogenizing buffer by a 
tight fi tting Dounce A homogenizer and used as the source of 
endoplasmic reticulum fraction to assay cytidinediphosphate-
diacylglycerol synthetase (CDS) activity. Phosphatidylglycero-
phosphate synthase (PGPS) and CL synthase (CLS) activities 
were determined as previously described ( 15, 17–19 ). CDS ac-
tivity was determined in mitochondrial fractions in accordance 
with the method given by Rusnak et al. ( 18 ). In other experi-
ments, 20   g of mitochondrial protein was assayed for mono-
lysocardiolipin (MLCL) and phosphatidic acid (PA) and 
phosphatidylglycerol (PG) production in the presence of 70,000 
dpm/nmol [1- 14 C]linoleneoyl CoA as described previously 
( 19–22 ). The reaction was performed at 37°C for 40 min follow-
ing which the [ 14 C]MLCL and [ 14 C]PA+[ 14 C]PG were isolated 
via thin-layer chromatography. 
anisms responsible for CL alterations during the develop-
ment of HF have not been previously investigated. 
 CL is  biosynthesized in a series of steps from phosphatidic 
acid and must then be  remodeled into a form which, in the 
heart, is linoleic acid (18:2) rich. Using electrospray ion-
ization mass spectroscopy, previous studies in SHHF rats 
and humans have shown a signifi cant decrease in the form 
of cardiac CL containing four 18:2 side chains, tetralinoleoyl 
CL ((18:2) 4 CL). This is the CL molecular species that 
comprises 70–80% of cardiac CL in the rat or human heart 
and is required for the activity of cytochrome oxidase ( 9, 
10 ). The contents of minor CL species containing oleic 
acid (18:1), arachidonic acid (20:4), and docosahexaenoic 
acid (22:6) were increased in failing SHHF rat and hu-
mans hearts, indicating that there is a switch to an alter-
nate form of CL remodeling during the development of 
HF. SD rats, which were free of pathology at the ages used, 
did not exhibit these drastic changes in CL ( 9 ). 
 In the present study, we examined the activity and 
mRNA expression of enzymes involved in CL biosynthesis 
and remodeling in the SHHF rat, a well-established con-
genital model of idiopathic dilated cardiomyopathy ( 11 ). 
The lean (Mcc fa cp  /   ) male SHHF rats used in this study 
typically exhibit severe hypertension by 5 months of age, 
which progresses to marked left ventricular hypetrophy by 
15 months, and overt HF by 21–24 months of age ( 8, 
12–14 ). To complement studies in the SHHF rat, left ven-
tricular (LV) tissue explanted from human HF patients 
and nonfailing Sprague Dawley (SD) rats were also exam-
ined. We hypothesized that alterations in CL biosynthetic 
and remodeling enzymes contribute to the CL alterations 
seen in the development of HF and may therefore repre-
sent targets for pharmacotherapeautic modulation. 
 MATERIALS AND METHODS 
 Materials 
 [ 14 C]Glycerol-3-phosphate, [5- 3 H]cytidine 5 ¢ -triphophate, 
[ 3 H]CDP-DAG, [1,3- 3 H]glycerol, [1- 14 C]linoleic acid, phosphatidyl
[ methyl - 3 H]choline, and [1- 14 C]linoleoyl CoA were obtained from 
either Dupont (Mississauga, ON, Canada), or Amersham (Oakville, 
ON, Canada). Phosphatidyl[ 14 C]glycerol was synthesized from 
[ 14 C]glycerol-3-phosphate as described previously ( 15 ). Lipid 
standards were obtained from Serdary Research Laboratories 
(Englewood Cliffs, NJ). Thin layer chromatographic plates (silica 
gel G, 0.25 mm thickness) were obtained from Fisher Scientifi c 
(Winnipeg, MB, Canada). Ecolite scintillant was obtained from 
ICN Biochemicals (Montreal, QC, Canada). All other chemicals 
were certifi ed ACS grade and obtained either from Fisher Scien-
tifi c or Sigma Chemical Co. (St Louis, MO). 
 Animal models 
 Male lean (Mcc facp  /   ) SHHF rats were obtained from the 
breeding colony maintained by S. A. M. at the University of Colo-
rado at Boulder. SD rats were purchased from Harlan (Indianap-
olis, IN). All animals were treated according to the guidelines 
established by the University of Colorado Institutional Animal 
Care and Use Committee and conform to the Guide for the Care 
and Use of Laboratory Animals published by the National Insti-
tutes of Health. 
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 TABLE 1. Sequence of primers used for real time PCR 
Target gene Species Accession number Forward primer Reverse primer Probe
Product 
length (bp)
Phoshatidylglycerolphosphate 
synthase (PGPS)
rat BG663105 5  ¢  -AGA GGT 
 GAA CGG CTT 
 CTT TGG -3  ¢  
5  ¢  -CAC TGT AGA 
 ACT GTC GCT 
 CAA TGTG 3  ¢  
SYBR Green 1 69
CDP-diacylglycerol 
synthase 1 (CDS-2)
rat NM_031242 5  ¢  -GGA GAT 
 TCC GAT 
 GTT CCT GA -3  ¢  
5  ¢  -CCA CGA ATC 
 CAC CAG TTC 
 TT- 3  ¢  
SYBR Green 1 110
CDP-diacylglycerol 
synthase 1 (CDS-2)
rat NM_053643.1 Applied Biosystems Taqman Gene Expression Assay: Assay Location-1057 113
Cardiolipin synthase
(CLS, CRD-1)
rat NM_001
014258.1
5  ¢  -TGG ATG GAT 
 TTA TTG CTC 
 GAA A -3  ¢  
5  ¢  -TGG GAC TGG 
 AAT AAG ATC 
 TGC AT -3  ¢  
5  ¢  -FAM-CAG CTT TGG 
 GAA GTG CTC TTG 
 ATC CAC T-TAMRA -3  ¢  
134
Tafazzin (TAZ) rat NM_001
025748.1
Applied Biosystems Taqman Gene Expression Assay:Assay Location-618 106
Acyl-CoA:lysocardiolipin 
acyltransferase-1 (ALCAT)
rat CO403431 5  ¢  - CAG AAG GAA 
 CTG ACC TCA 
 CAG AAA A -3
5  ¢  - GTG GTT CTT 
 GGG TGT AAT 
 ACA TAC TCA-3  ¢  
5  ¢  - FAM-TTC TCA GCA 
 AAA TCG-NFG-3  ¢  
123
CDP-diacylglycerol 
synthase 2 (CDS-2)
human NM003818.2 Applied Biosystems Taqman Gene Expression Assay:Assay Location-647 83
Cardiolipin synthase (CLS) human NT011387 5  ¢  -TGG ATG GAT 
 TTA TTG CTC 
 GAA A -3  ¢  
5  ¢  -TGG AAC TGG 
 AAT AAG ATC 
 TGC AT -3  ¢  
5  ¢  -FAM-CAG CTT TGG 
 GAA GTG CTC TTG 
 ATC CAC T-TAMRA -3  ¢  
136
Tafazzin (TAZ) human NM181311.1 Applied Biosystems Taqman Gene Expression Assay:Assay Location-539 87
 RNA isolation and real time PCR assay 
 Standard RNA was prepared from LV tissue samples by the T7 
polymerase method as previously described by Young et al. ( 23 ). 
cDNA standards for tafazzin (TAZ) were derived from cDNA 
clones containing the appropriate assay specifi c sequences ob-
tained from Invitrogen Corporation (clone ID 7387882 and 
7312046, respectively). The absolute quantifi cation for CLS was 
determined by the input copy number of the transcript of inter-
est with the PCR signal to a standard curve. The same total sam-
ple RNA (300 ng) was used for each quantitative RT-PCR reaction 
and reaction conditions were as previously described ( 24–26 ). To 
quantify PGPS and CDS-1, SYBR Green 1 was used due to the 
unavailability of specifi c probes. Since SYBR Green 1 can detect 
specifi c and nonspecifi c PCR products as it can bind to double 
standard DNA in a sequence independent manner ( 27 ), a melt-
ing curve analysis was performed at the end of each experiment 
to confi rm the absence of primer-dimers in specifi c PCR prod-
ucts. Primer sequences are shown in  Table 1 . Each real time PCR 
procedure was carried out in duplicates, and at least three sepa-
rate experiments were performed. All PCR results used mRNA 
copy number normalized to either the youngest or the nonfail-
ing group to facilitate clear comparisons between species. 
 Statistical analysis 
 Data are expressed as means ± SEM. The differences between 
two groups were evaluated by Student’s  t -test. The data from 
more than two groups were evaluated by one-way ANOVA fol-
lowed by the Tukey test. Values showing  P < 0.05 were considered 
statistically signifi cant unless otherwise indicated. 
 RESULTS 
 Echocardiographic analysis and general characteristics of 
SHHF rats 
 Between the ages of 2 and 15 months, echocardio-
graphic data from SHHF rats indicated signifi cant in-
creases in LV chamber diameter and wall thickness with 
only minor decreases in EF or FS, consistent with the de-
velopment of compensated LV hypertrophy resulting from 
chronic hypertension ( Table 2 ). From the age of 15 
months to 22 months, hearts exhibited pronounced LV 
chamber dilatation, anterior wall thickening, and contrac-
tile dysfunction. PWT decreased signifi cantly from 15 
months to terminal HF. All of these changes are consistent 
with the late stages of disease in this model. 
 Cardiac hypertrophy was also refl ected by increased 
heart weight, LV, right ventricle, and heart-to-body-weight 
ratios at 15 and 22 months of age compared with 2-month-
old animals ( Table 3 ). The presence of pulmonary edema 
in 15- and 22-month-old animals was refl ected by 24% and 
120% increases in the wet weight of lungs, respectively. 
Signifi cant increases in left and right kidney weights at 15 
and 22 months refl ect a severely compromised kidney 
function in these animals. Likewise, the liver weight was 
increased by 39% and 65% in 15- and 22-month-old SHHF 
rats, respectively. 
 Alterations in enzyme activities and products involved in 
CL biosynthesis 
 Previous studies have shown a decrease in the total 
amount of CL in interfi brillar mitochondria during the 
development of HF in SHHF rat hearts and in LV tissue in 
human HF patients ( 8 ). To investigate the biochemical al-
terations in CL biosynthesis during the development of 
HF, three enzymes involved in the biosynthetic pathway of 
CL were studied: CDS, PGPS, and CLS. All studies were 
carried out with LV tissue as SHHF rats exhibit selective 
LV contractile dysfunction ( 28 ). 
 CDS.  The activity of CDS, a rate limiting enzyme in CL 
biosynthesis ( 15, 19, 29 ), was increased signifi cantly at 15 
and 22 months in comparison to 2-month-old SHHF rats 
( Fig. 1A ) , while CDS activity in the endoplasmic reticulum-
rich microsomal fraction remained unaltered in the pro-
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mRNA expression pattern was somewhat different, increas-
ing by 15 months of age in the SHHF rat but decreasing 
again at 22 months ( Fig. 2B ). This difference could indi-
cate posttranslational control of PGPS activity. The amount 
of PA+PG formed, which is an indication of the activity of 
the enzyme activities up to the CLS step (see  Fig. 5 ), was 
reduced by 45% and 48% in 15- and 22-months-old SHHF 
rats, respectively ( Table 4 ). 
 CLS.  The activity of CLS in the mitochondrial fraction was 
decreased by 20% at 15 months of age and 57% by 22 months 
of age ( Fig. 3A ). Likewise, the gene expression of CLS was 
decreased by 50% and 80% in 15- and 22-months-old SHHF 
rats, respectively ( Fig. 3B ). Human mRNA, however, showed 
no signifi cant alterations in CLS mRNA ( Fig. 3C ). 
 Alterations in CL remodeling 
 There are major alterations in CL composition in SHHF 
rats and humans during HF ( 8, 9 ) suggesting an alteration 
of CL remodeling. 
 MLCL AT and acyl-CoA: lysocardiolipin acyltransferase-1 
(ALCAT1) 
 In SHHF rats, the rate of formation of MLCL, an inter-
mediate product in the remodeling of CL ( 20 ), was re-
duced by 50% in 15-months-old SHHF and 36% in 
22-months-old SHHF rats compared with 2- months-old 
animals ( Table 4 ). MLCL AT activity, which can place an 
acyl group on the MLCL, was increased 3- and 5-fold in 
15- and 22-months-old SHHF rats, respectively, compared 
with 2-months-old rats ( Fig. 4A ). On the other hand, the 
gene expression of ALCAT1, an endoplasmic reticulum 
(ER) MLCL AT ( 33 ), remained unaltered at different age 
groups of SHHF rats ( Fig. 4B ). 
 TAZ.  Gene expression of tafazzin (TAZ), which encodes 
a CL transacylase involved in CL remodeling ( 34 ), was sig-
nifi cantly reduced in 15- and 22-months-old SHHF rats 
compared with 2-months-old animals ( Fig. 4C ). It also was 
decreased in failing human hearts ( Fig. 4D ). This is a 
novel fi nding in that it is the fi rst indication that the CL 
changes seen in HF may be infl uenced by the same gene 
altered in Barth Syndrome. No signifi cant changes in TAZ 
expression were seen in nonfailing hearts from SD rats 
( Fig. 4E ). 
 DISCUSSION 
 In the present study, we observed discordant regulation 
of CL biosynthetic and remodeling enzymes at the activity 
and gene expression level in hypertensive, preHF, and HF 
in SHHF rats. The results are summarized in the pathway 
shown in  Fig. 5 . In mammalian heart, de novo biosynthesis 
of CL begins in the mitochondrial membrane initially 
by the conversion of PA to cytidine-5 ¢ -diphosphate-1,
2-diacylglycerol (CDP-DAG) catalyzed by CDS. Pulse chase 
labeling studies in the isolated rat heart indicated that 
CDS catalyzes a rate limiting step in CL de novo biosynthe-
sis ( 19 ). Since CDS enzyme activity is localized to both the 
gression to HF ( Fig. 1B ). There are two known genes 
coding for CDS: CDS-1 and CDS-2. In HF, CDS-1 mRNA 
levels mimic mitochondrial activity ( Fig. 1C ), but CDS-2 
mRNA levels fall in both SHHF rats and humans ( Figs. 1D, 
1E ) but are unaffected in SD rats ( Fig. 1F ). Because of 
limited availability of human heart tissue, no attempt was 
made to check the status of CDS-1 mRNA in humans. 
Northern blot studies performed by Lykidis et al. ( 30 ) 
have shown no expression of CDS-1 mRNA in human 
heart. However, another study indicated the presence of 
CDS-1 mRNA in human heart ( 31 ). These differences may 
have been due to cross-hybridization of CDS-1 probes with 
CDS-2 mRNA ( 32 ). 
 PGPS.  The activity of PGPS, the committed step in CL 
biosynthesis, in the mitochondrial fraction was increased 
by 21% and 98% at 15 and 22 months of age in compari-
son to 2-month-old SHHF rats, respectively ( Fig. 2A ). The 
 TABLE 2. Echocardiographic parameters of 2-, 15- and 
22-month-old SHHF rats 
Parameter 2 months 15 months 22 months
LVIDd (mm) 7.2 ± 0.1 8.0 ± 0.3 a 10.4 ± 0.4 b , d 
LVIDs (mm) 4.7 ± 0.2 5.3 ± 0.3 a 8.2 ± 0.3 b ,d 
FS (%) 36 ± 1.0 33 ± 2.0 21 ± 2.0 b ,d 
EF (%) 74 ± 1.0 70 ± 2.0 51 ± 3.0 b ,d 
AWTd (mm) 1.4 ± 0.1 2.0 ± 0.1 b 2.6 ± 0.2 b , c 
PWTd (mm) 1.5 ± 0.1 2.3 ± 0.2 b 1.9 ± 0.1 a , c 
Values are mean ± SEM. AWTd, left ventricular anterior wall thickness 
in diastole; EF, ejection fraction; FS, fractional shortening; LVIDd, left 
ventricular internal diameter in diastole; LVIDs, left ventricular internal 
diameter in systole; PWTd, left ventricular posterior wall thickness in 
diastole; SHHF, spontaneously hypertensive heart failure.
 a P < 0.05 vs. 2 month.
 b P < 0.001 vs. 2 month.
 c P < 0.01 vs. 15 month
 d P < 0.001 vs. 15 month.
 TABLE 3. General characteristics of 2-, 15- and 22-month-old 
SHHF rats 
Parameter 2 months 15 months 22 months
n 12 6 4
BW (g) 240 ± 4.7 396 ± 10.5 c 398 ± 12.0 c 
HW (mg) 916 ± 85 1545 ± 37 c 2442 ± 164 c 
HW/BW (mg/g × 
100)
382 ± 18.1 390 ± 3.5 613 ± 13.6 c,f 
LVW (mg) 447 ± 15.8 750 ± 31.5 c 942 ± 28.5 c,e 
RVW (mg) 210 ± 14.5 286 ± 21.0 a 450 ± 29.1 c,f 
Liver wt (g) 10.7 ± 0.24 14.85 ± 0.48 c 17.69 ± 1.47 c,e 
Right kidney wt 
(g)
0.91 ± 0.02 1.41 ± 0.03 2.35 ± 0.48 c,d 
Left kidney wt (g) 0.92 ± 0.03 1.39 ± 0.02 2.40 ± 0.47 c,e 
Lung wt (g) 1.50 ± 0.05 1.87 ± 0.04 a 3.32 ± 0.19 c,f 
Values are mean ± SEM; n = number of rats. BW, body weight; 
HW, heart weight; HW/BW, heart weight-to-body weight ratio; LVW, 
left ventricular weight; RVW, right ventricular weight; SHHF, 
spontaneously hypertensive heart failure.
 a P < 0.05 vs. 2 month.
 b P < 0.01 vs. 2 month.
 c P < 0.001 vs. 2 month.
 d P < 0.5 vs. 15 month.
 e P < 0.01 vs. 15 month.
 f P < 0.001 vs. 15 month.
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claimed that CDS-1 did not seem to encode the mitochon-
drial specifi c isozyme in COS-7 cells ( 30 ). It has been 
shown previously that an increase in CDS activity was as-
sociated with increased secretion of the pro-infl ammatory 
mediators, tumor necrosis factor-  , and interleukin-6, 
from ECV304 cells upon stimulation with interleukin-1  
( 36 ). An increase in tumor necrosis factor-  and interleu-
kin-6 content has been observed in SHHF rats at 15 months 
of age ( 12 ), indicating that increased CDS activity as ob-
served in the present study may be related to the increased 
secretion of these infl ammatory mediators, which are 
known to cause contractile dysfunction ( 37 ). However, 
further studies are needed to fi nd a direct relationship be-
tween contractile dysfunction, CDS activity, and release of 
pro-infl ammatory mediators at compensated and terminal 
stages of HF in SHHF rats. 
endoplasmic reticulum and mitochondria, we measured 
its activity in both these subcellular fractions in the hearts 
of SHHF rats. Interestingly, the activity of cardiac CDS was 
increased in the mitochondrial fraction during HF devel-
opment in SHHF rats. In contrast, there were no altera-
tions in CDS enzyme activity in cardiac microsomal 
fractions prepared from these animals. A previous study in 
rat liver concluded that CDS enzyme activity may be regu-
lated differently in endoplasmic reticulum and mitochon-
dria ( 35 ). The current study supports that observation and 
extends alternate regulation of CDS enzyme activity to the 
heart.  Fig. 1 shows that CDS-1 and CDS-2 mRNA were in-
versely altered during HF development in SHHF rats, sug-
gesting an interplay between these two transcripts. CDS-1, 
which mimics the mitochondrial CDS activity, may be the 
larger infl uence on the activity, although a previous study 
 Fig. 1. Cytidinediphosphatediacylglycerol synthetase (CDS) activity and real time PCR from LV tissue. (A) 
Activity in mitochondrial fraction from SHHF rats; (B) Activity in microsomal endoplasmic reticulum frac-
tion from SHHF rats; (C) CDS-1 mRNA from SHHF rats; (D) CDS-2 mRNA from SHHF rats; (E) CDS-2 
mRNA in human nonfailing (NF) or idiopathic dilated cardiomyopathy (IDC); and (F) CDS-2 mRNA from 
Sprague Dawley rats. All PCR data is expressed as mean ± SEM with the young rats or NF humans as 100%. 
N = 4 (rats) and 10 (humans) per group. * P < 0.05 vs. 2 month SHHF rats or NF humans. SHHF, spontane-
ously hypertensive heart failure. 
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 The committed step of CL biosynthesis is the condensa-
tion of CDP-DAG with  sn -glycerol-3-phosphate to form PG 
phosphate catalyzed by PGPS ( 38 ). Both PGPS enzyme ac-
tivity and its mRNA expression were increased at 15 months 
in SHHF rats compared with 2-months-old animals. PGPS 
activity was further increased in 22-months-old SHHF rats. 
The difference in the pattern of PGPS activity and expres-
sion may be related to possible post-translational modifi ca-
 Fig. 2. Phosphatidylglycerolphosphate synthase (PGPS) activity 
and real time PCR from LV tissue. (A) Activity from SHHF rats and 
(B) mRNA from SHHF rats. PCR data is expressed as mean ± SEM 
with the young rats as 100%. N = 4, * P < 0.05 vs. 2-month SHHF 
rats. SHHF, spontaneously hypertensive heart failure. 
 TABLE 4. Alterations in mitochondrial products formed in SHHF 
rat heart during de novo synthesis and remodeling of cardiolipin 
Specifi c activity 
(pmol/min/mg) 2 months 5 months 22 months
PA + PG formed 78.5 ± 5.2 43.0 ± 1.3 a 41.1 ± 4.3 a 
MLCL formed 17.3 ± 1.2 8.8 ± 0.3 b 11.0 ± 0.5 a 
Values are mean ± SEM. MLCL, monolysocardiolipin; PA, 
phosphatidic acid; PG, phosphatidylglycerol; SHHF, spontaneously 
hypertensive heart failure.
 a P < 0.01 vs. 2 month.
 b P < 0.001 vs. 2 month.
 Fig. 3. CL synthase (CLS) activity and real time PCR from LV tis-
sue. (A) Activity from SHHF rats; (B) CLS mRNA from SHHF rats; 
and (C) CLS mRNA in human nonfailing (NF) or idiopathic di-
lated cardiomyopathy (IDC). All PCR data is expressed as mean ± 
SEM with the young rats or NF humans as 100%. N = 4 (rats) and 10 
(humans) per group. * P < 0.05 vs. 2-month SHHF rats or NF hu-
mans. SHHF, spontaneously hypertensive heart failure. 
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tion of the enzyme in HF. Due to the unavailability of 
commercially available immunoprecipitating antibodies 
for PGPS, the translational level of this transcript was not 
measured in the present study. A previous study showed, 
using an epitope-tagged Pgs1p, that PGPS enzyme activity 
could be modifi ed by phosphorylation in  Saccharomyces 
cerevisiae ( 39 ). The possibility of post-translational alteration 
of PGPS during the development of HF will form the basis 
for a future study. The fi nal step of mammalian de novo 
CL biosynthesis involves the conversion of CDP-DAG and 
PG to CL and is catalyzed by CLS ( 29, 40 ). CLS enzyme 
activity and its mRNA expression were decreased during 
the development of HF in SHHF rats but not in humans. 
The decreased enzyme activity of CLS in mitochondria as 
well as attenuated gene expression of CLS may be respon-
sible for the observed decrease in CL content at 15 and 22 
months of HF in SHHF rats. The disparity of the human 
data from the rat data may be due to large variations in the 
human subjects, genetic differences between rats and hu-
mans, or pharmaceutical interventions that these patients 
underwent before transplant. 
 The present study indicates that although CDS and 
PGPS enzyme activities were increased, the ability to sus-
tain substrates for CL de novo biosynthesis during devel-
opment of HF in SHHF rats was still compromised, at least 
in interfi brillar mitochondria. This was confi rmed by the 
decreased amount of [1- 14 C]linoleate incorporated into 
PA+PG formed in mitochondria at 15 and 22 months in 
SHHF rats compared with 2-months-old animals. The de-
creased availability of CTP, which is known to regulate the 
CL biosynthesis in isolated heart ( 40 ), may account for 
such a decrease in PA+PG in compensated and terminal 
 Fig. 4. CL remodeling enzyme activity and real time PCR from LV tissue. (A) Activity of monolysocardio-
lipin acyltransferase (MLCL AT) in SHHF rats; (B) Acyl-CoA: lysocardiolipin acyltransferase 1 (ALCAT1) 
mRNA from SHHF rats; (C) Tafazzin (TAZ) mRNA from SHHF rats; (D) TAZ mRNA in human nonfailing 
(NF) or idiopathic dilated cardiomyopathy (IDC); and (E) TAZ mRNA from Sprague Dawley rats. All PCR 
data is expressed as mean ± SEM with the young rats or NF humans as 100%. N = 4 (rats) and 10 (humans) 
per group. * P < 0.05 vs. 2-month SHHF rats or NF humans. SHHF, spontaneously hypertensive heart 
failure. 
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CAT1 in the ER for the resynthesis of CL remains to be 
determined. Newly synthesized CL also undergoes hydro-
lytic degradation via deacylation to MLCL in mammalian 
tissues via phospholipase A 2 (PLA 2 ) ( 45 ). Alterations in 
Ca 2+ -independent PLA 2 (iPLA 2 ) have been shown to con-
tribute to diminished cardiac function in failing hearts 
due to myocardial infarction ( 46 ). Although a recent study 
by Mancuso et al. ( 47 ) has demonstrated that genetic abla-
tion of iPLA2  causes a signifi cant decrease in tetra 18:2 
CL with abnormal mitochondrial function, no attempt was 
made to check the status of different PLA 2 in SHHF rats. 
Further studies targeting specifi cally at the catabolism of 
CL are needed to address this complex issue in SHHF rats. 
Nevertheless, this study is the fi rst to suggest that altera-
tions in functional  Taz gene expression may contribute to 
HF in the absence of Barth Syndrome. Factors responsible 
for regulating  Taz gene expression in the healthy and dis-
eased heart are unknown and are currently being investi-
gated in our laboratories. 
 To our knowledge, this is the fi rst study showing the pat-
tern of alterations in various enzymes involved in CL bio-
synthesis and remodeling in HF. Since the SHHF rat model 
has been shown to exhibit common signs of human HF ( 8, 
12 ), this study provides the preeminent characterization 
between compensated and later stages of HF. Though the 
data in this study on humans is limited, it gives an insight 
into the similarities (and differences in the case of CLS) 
present between humans and SHHF rats in failure. The 
SD rat data also serves to distinguish between HF and non-
pathological aging, which is an important distinction, es-
pecially with CL, which for years was presumed to decrease 
with age and has now been shown to have mostly patholo-
gy-related alterations ( 8 ). 
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